Efficacy

Cosela (Trilaciclib) for Small Cell Lung Cancer

Cosela (trilaciclib) is a novel therapeutic agent approved by the U.S. Food and Drug Administration (FDA) for use in patients with extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is designed to protect bone marrow cells from the damage caused by chemotherapy. Clinical trials have shown that Cosela, when administered before chemotherapy, can significantly reduce the occurrence of chemotherapy-induced myelosuppression. This reduction in myelosuppression can lead to fewer chemotherapy dose delays and reductions, thereby allowing patients to receive their chemotherapy on schedule, which is critical for the treatment of aggressive cancers like ES-SCLC.

The efficacy of Cosela in improving myelosuppression outcomes was demonstrated in randomized, placebo-controlled trials. Patients who received Cosela experienced a lower incidence of severe neutropenia, a condition where white blood cell counts drop to dangerously low levels, increasing the risk of serious infection. By mitigating this adverse effect of chemotherapy, Cosela helps maintain the patient's immune system function during treatment for small cell lung cancer.

Exkivity (Mobocertinib) for Non-Small Cell Lung Cancer

Exkivity (mobocertinib) is an oral medication specifically approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, who have received platinum-based chemotherapy. Mobocertinib is a tyrosine kinase inhibitor that targets the underlying genetic drivers of tumor growth and proliferation in this subset of lung cancer patients.

The approval of Exkivity was based on the results of a multicenter, open-label, single-arm clinical trial, which demonstrated a significant response rate in patients with EGFR exon 20 insertion-positive NSCLC. The trial reported a meaningful reduction in tumor size in a substantial proportion of patients treated with mobocertinib. Additionally, the duration of response observed in the trial indicated that Exkivity could offer a sustained therapeutic benefit for patients with this specific type of lung cancer mutation who have limited treatment options.